- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00814450
Safety & Accuracy of the ActiSight Needle Guidance System in Percutaneous Chest Aspiration and Biopsy (ANGS-PCAB)
December 29, 2009 updated by: ActiViews Ltd.
A Prospective, Open-Label, Single-Arm, Single-Center Study Evaluating The Preliminary Safety And Accuracy Of The Actisight™ Needle Guidance System In Patients Undergoing CT-Guided Percutaneous Chest Aspiration And Biopsy
This study is intended to provide clinical data regarding safety and accuracy of the ActiSight™ Needle Guidance System in assisting Chest CT guided biopsies.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tel Aviv, Israel, 64239
- Tel Aviv Sourasky Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects, 18 years of age or older at the time of enrollment
- Subjects meeting all medical conditions for percutaneous chest aspiration/biopsy with safe path to lesion between ribs, however, not in the breast area in women or men with gynecomastia
- Single target pulmonary lesion greater than 10 mm in size (diameter) and depth of lesion greater than 40 mm from the skin
- INR <1.3
- Written informed consent to participate in the study
- Ability to comply with the requirements of the study procedures
Exclusion Criteria:
- Fibrous tissue or cyst in access path (not including target lesion)
- Hemophilia, thrombocytopenia, coagulopathy, or other elevated risk for bleeding or abnormal clotting
- Central lesion is located in radius of less than 2 cm from lobar blood vessels and the heart.
- The selected needle path has a safety margin of less than 2 cm from major blood vessels and the heart
- Use of ticlopidine or similar antithrombotic medication
- For subjects taking warfarin or other anticoagulant medication, INR >1.3
- Pulmonary hypertension, heart failure, renal failure, or blood dyscrasia
- Subjects who cannot tolerate mild sedation
- Subjects with FEV1 < 800 mL unless approved by principal investigator following consultation with multidisciplinary team
Subjects with the following laboratory values, unless approved by hematologist:
- Platelet count <100,000/mL
- APTT >39 sec or PT >15 sec
- Pregnancy or lactation
- Patient is unable to comply with requirements of the procedure, i.e. holding breath
- Participation in an investigational trial within 30 days of enrollment
- Any form of substance abuse (including drug or alcohol abuse), psychiatric disorder, or any chronic condition that could, in the opinion of the investigator, of interfering with the conduct of the study.
- Subjects who are uncooperative or cannot follow instructions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of target reached within a radius of 8 mm from the preplanned targeted point as measured on the final CT scan.
Time Frame: Measure evaluated during entire course of study
|
Measure evaluated during entire course of study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of needle punctures through the skin
Time Frame: Measure evaluated during entire course of study
|
Measure evaluated during entire course of study
|
Number of needle punctures through the pleura
Time Frame: Measure evaluated during entire course of study
|
Measure evaluated during entire course of study
|
Number of CT scans needed
Time Frame: Measure evaluated during entire course of study
|
Measure evaluated during entire course of study
|
Radial distance at target plane at the needle's final position as shown on the ActiSight screen
Time Frame: Measure evaluated during entire course of study
|
Measure evaluated during entire course of study
|
Adverse events following the procedure, including the following:Pneumothorax, Hemoptysis >100 ml, Bleeding, Collapsed lung, Chest drainage, Need for hospitalization
Time Frame: Measure evaluated during entire course of study
|
Measure evaluated during entire course of study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Boaz Tiran, MD, Tel-Aviv Sourasky Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2008
Primary Completion (ACTUAL)
June 1, 2009
Study Completion (ACTUAL)
June 1, 2009
Study Registration Dates
First Submitted
December 23, 2008
First Submitted That Met QC Criteria
December 23, 2008
First Posted (ESTIMATE)
December 24, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
December 30, 2009
Last Update Submitted That Met QC Criteria
December 29, 2009
Last Verified
December 1, 2009
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ASNG-LFNA-101-IL (Other Identifier: Protocol #)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biopsy
-
Clear Guide MedicalNational Institutes of Health (NIH); Temple UniversityWithdrawnLiver Biopsy | Lung Biopsy | Kidney BiopsyUnited States
-
Yonsei UniversityRecruitingLiver Biopsy | Image-guided BiopsyKorea, Republic of
-
Mauna Kea TechnologiesCompletedLung Percutaneous Biopsy | Liver Percutaneous BiopsyFrance
-
Washington University School of MedicineCompletedBiopsy, Fine-Needle | Endosonography | Biopsy, Fine-Needle/MethodsUnited States
-
Mauna Kea TechnologiesCompletedLiver Percutaneous Biopsy or Ablation | Kidney Percutaneous Biopsy or AblationFrance
-
Taipei Medical University WanFang HospitalCompleted
-
University of California, DavisCompleted
-
ActiViews Ltd.Completed
-
Medical University of BialystokRecruiting
-
AdventHealthCompleted
Clinical Trials on Biopsy needle guidance system (ActiSight™)
-
ActiViews Ltd.Tel-Aviv Sourasky Medical CenterCompleted
-
ActiViews Ltd.Completed
-
ActiViews Ltd.CompletedLiver Diseases | Lung DiseasesIsrael
-
ActiViews Ltd.Completed
-
ActiViews Ltd.Completed
-
University of AlbertaCompletedLymphoma | Pancreas Adenocarcinoma | Pancreas Neoplasms | Gastrointestinal Stromal TumorCanada
-
NeoDynamics ABRecruitingBreast CancerUnited Kingdom
-
University of British ColumbiaPacific Centre for Reproductive MedicineTerminated
-
The Cleveland ClinicCompleted
-
Uro-1 MedicalRecruiting